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1. Introduction
Common genetic risk factors have been associated with type 1 diabetes (T1D) and autoimmune
thyroid diseases (AITD). Graves’ disease (GD) and Hashimoto’s thyroiditis (HT) are typical
AITD. T1D and AITD are major components of autoimmune polyendocrine syndrome (APS)-2
and/or APS-3. The human leukocyte antigen (HLA) has been extensively studied in these
diseases [1]. However, population studies have shown that HLA associations may vary
depending on the ethnic origin [2]. In Caucasian populations, the highest-risk HLA haplotype
for T1D is DRB1*03:01-DQA1*05-DQB1*02 (DR3) and/or DRB1*04-DQA1*03:01-DQB1*03:02
(DR4) [2, 3], and the corresponding haplotype for AITD is DR3 [4, 5]. DRB1*15-DQB1*06:02
and DRB1*07:01-DQA1*02:01 (DR7) haplotypes confer strong protection against both T1D [2,
3] and AITD [6, 7]. However, in the Japanese population, the DR3 haplotype is absent, and the
DR4 and DR7 haplotypes are rare [8–10], which may be more helpful for examining the
susceptibility and resistance to T1D and AITD of HLA DR-DQ haplotypes, with the exception
of DR3, DR4, and DR7.
DR3 and DR4 haplotypes occur very frequently among Caucasian patients with T1D, and only
a small percentage (approximately 10%) of Caucasian patients with T1D carry neither of these
haplotypes [11, 12]. At the DQB1 locus, “non-Asp” alleles, which code for an amino acid other
than aspartate at codon 57, confer an increased risk for T1D in Caucasian populations [13]. The
risk due to DR4 haplotypes is primarily attributable to an association with the DQB1*03:02
allele, which codes for an Ala at codon 57 [14]. The risk conferred by the DR3 haplotype may
be associated with DQA1 alleles that encode the amino acid Arg at codon 52, such as
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DQA1*05:01 [15]. Recently, a similar mechanism was shown to be important in the etiology of
AITD. Tomer et al. identified an Arg at position 74 of the HLA-DRβ1 chain (DRβ-Arg-74),
encoded by the DRB1*03:01 allele, as the critical DR amino acid conferring susceptibility to GD
[16, 17]. Further analysis has shown that the presence of Gln at position 74 was protective not
only for GD [16] but also for APS-3 [18].
In the Japanese population, in contrast to Caucasians and other Asians, the DRB1*04:05-
DQA1*03:03-DQB1*04:01 haplotype, which differs from the DR4 haplotype in Caucasians, and
the DRB1*08:02-DQA1*03:01-DQB1*03:02, DRB1*09:01-DQA1*03:02-DQB1*03:03 (DR9), and
DRB1*13:02-DQA1*01:02-DQB1*06:04 (DR13) haplotypes confer susceptibility to T1D [9, 19].
The DRB1*15:01-DQB1:06:02, DRB1*15:02-DQB1*06:01, and DRB1*08:03-DQB1*06:01 haplo‐
types confer protection against T1D [9, 10, 19]. On the other hand, the DRB1*08:03-DQB1*06:01
and DR9 haplotypes confers susceptibility to AITD [19–23], whereas the DR13 and
DRB1*15:01-DQB1:06:02 haplotypes confer protection against AITD [7, 23–29]. Taken together,
regarding susceptibility and resistance to T1D and AITD, the DR3, DR4, DR7, DR9, and
DRB1*15:01-DQB1:06:02 haplotypes have the same effect. On the contrary, DRB1*08:03-
DQB1*06:01 and DR13 haplotypes have an adverse effect on these diseases.
In this chapter, we will review HLA class II genes that confer susceptibility and resistance to
T1D and AITD, and discuss the relationship between HLA class II genes and T1D, AITD, and
APS-3. Furthermore, we focus on amino acids at position 74 of the HLA-DRβ1 chain, position
52 of the HLA-DQα1 chain, and position 57 of the HLA-DQβ1 chain as key factors involved
in susceptibility and resistance to T1D and AITD, and we discuss key amino acids and their
involvement in susceptibility and resistance to T1D and AITD.
2. Nomenclature
In 1980, Neufeld and Blizzard suggested a classification of APS based on clinical criteria alone,
and described four main types [30]. Of the four types, APS-2 and APS-3 are mainly associated
with AITD and/or T1D. APS-2 is characterized by Addison’s disease (AD) associated with
AITD and/or T1D. APS-2 is quite rare with an incidence of 1.4-4.5 cases for every 100,000
individuals [31, 32]. While all patients with APS-2 have AD [30, 32–35], AITD and T1D are
reported to occur in 69–82% and 30–52% of patients with APS-2, respectively [30, 34, 35]. APS-3
has been defined as an association between a clinical entity of AITD and an additional
autoimmune disease such as T1D (Type 3A), chronic atrophic gastritis, pernicious anemia
(Type 3B), vitiligo, alopecia, myasthenia gravis (Type 3C). AD and/or chronic hypoparathyr‐
oidism were categorically excluded from APS-3 [30]. Although AITD consists of HT, idiopathic
myxedema, asymptomatic thyroiditis, GD, endocrine ophthalmopathy, and pretibial myxe‐
dema, GD or HT comprise the majority of AITD. Thus, in discussing the relationship between
HLA and T1D and/or AITD, it is necessary to focus on APS type 3A (APS-3A) rather than
APS-2 or APS type 3B/3C, and GD or HT may be considered as AITD.
In Caucasian populations, including those in Northern Europe, the incidence rates of T1D are
high, in excess of 30 cases/100,000 individuals per year. In contrast, the Japanese population
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has one of the lowest incidence rate of T1D in the world, at 1.6 cases/100,000 individuals per
year, suggesting that the Japanese population may either lack an important susceptibility gene
or have a unique T1D protective gene [36, 37]. However, AITD is the most frequent autoim‐
mune disease in the population, present in approximately 7–8% of the general population [38,
39]. When thyroid disease is caused by environmental factors such as levels of iodine, incidence
rates have been found to vary between locations and over time [40–43]. Studies regarding the
incidence rates of AITD have come from a limited range of geographical areas. Therefore, it is
difficult to comment on the absence or presence of variances in incidence rates of AITD
between different geographical locations. Coexistence of T1D and AITD is common, with 15
to 30% of T1D subjects having AITD [44–46], whereas the prevalence of glutamic acid decar‐
boxylase antibodies (GADAb) in AITD patients is around 5% [47, 48]. There is a need to
distinguish T1D with AITD (T1D+AITD, APS-3A) from T1D without AITD (T1D-AITD).
Conversely, we may not need to distinguish AITD with T1D from AITD without T1D (AITD-
T1D). Abbreviations are listed in Table 1.
Abbreviations
AITD
T1D
GD HT
AITD-T1D
GD-T1D + - -
HT-T1D - + -
T1D-AITD - - +
T1D+AITD (APS-3A)
T1D+GD + - +
T1D+HT - + +
+, present; -, absent
Table 1. Relationship among T1D, AITD, and APS-3A
3. T1D
HLA class II genes are closely related to the onset of T1D in all ethnic groups. Recently,
Thomson et al. investigated whether HLA DR-DQ haplotypes and genotypes show the same
relative predispositional effects across populations and ethnic groups using data from 38
studies worldwide [49]. They introduced a new static, the patient/control (P/C) ratio of
haplotype or genotype frequencies within a study that allows comparison of absolute pene‐
trance values within and across studies. Mean P/C ratios are listed in Table 2. When the mean
P/C ratio is >1.10, we consider that the haplotype confers susceptibility to T1D, whereas when
the mean P/C ratio is <0.90, we consider that the haplotype confers protection against T1D.
When the mean P/C ratio is 0.90–1.10, we consider the haplotype as neutral to T1D.
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DRB1 DQB1 Mean P/C ratio Effect on T1D a
*01 *05:01 0.85 P
*03:01 *02 3.72 S
*04 *03:01 0.73 P
*04:01 *03:02 6.23 S
*04:02 *03:02 5.10 S
*04:03 *03:02 0.64 P
*04:05 *03:02 7.15 S
*04:05 *04:01 2.35 S
*04:06 *03:02 0.31 P
*07:01 *02 0.66 P
*08 *03:02 3.25 S
*08 *04:02 1.92 S
*08:03 *06:01 0.38 P
*09:01 *03:03 1.12 S
*12 *03:01 0.47 P
*13 *06:04 0.93 N
*14 *03:01 0.25 P
*15 *06:01 0.46 P
*15 *06:02 0.22 P
*16 *05:02 0.95 N
a Effect on T1D is classified as: S, susceptible; N, neutral; P, protective.
Table 2. DRB1-DQB1 haplotype P/C ratios with regard to susceptibility to T1D
4. AITD
The results of HLA association studies in AITD have been less consistent than in T1D.
Moreover, data on HLA haplotypes in HT have been less definitive than on those in GD. A
general methodological problem has been disease definition [50]; though the diagnosis of GD
may be relatively straightforward, the definition of HT has been more controversial. Three
varieties of thyroid autoantibodies are commonly used and widely available in clinical
diagnostic laboratories: anti-thyroglobulin antibodies (TgAb), anti-thyroid peroxidase
autoantibodies (TPOAb), and antibodies to thyrotropin receptor (TRAb). TgAb and TPOAb
are found in almost 100% of patients with HT, whereas these antibodies are also detectable in
50% to 90% of patients with GD and are common in the general population. The low levels of
TPOAb and TgAb found in many individuals are of uncertain significance in the presence of
normal thyroid function [51].
Table 3 shows previous reports on the relationship between HLA class II and AITD. The most
probable HLA-DR and -DQ haplotypes were deduced from linkage disequilibria [8–10].
Alleles in parentheses following the reference number indicate that the reference reported
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susceptibility or resistance of the allele, but not the haplotype, to the disease. There is no
parenthesis following the reference number if the references reported susceptibility or
resistance with 4-digit DRB1-DQB1, DQA1-DQB1, or DRB1-DQA1-DQB1 haplotypes. In cases
with more than 2 haplotypes sharing the same allele, the allele is listed redundantly in each
haplotype. However, considering the ethnicities that the references examined, the allele is
removed from the corresponding haplotypes; for example, the DRB1*08:02-DQA1*03:01-
DQB1*03:02 haplotype is rare in Caucasian populations [49] and thus in the reference exam‐
ining Caucasian populations, the DQA1*03:01 allele is listed only in the DRB1*04:01-
DQA1*03:01-DQB1*03:02 haplotype, and not in the DRB1*08:02-DQA1*03:01-DQB1*03:02
haplotype.
DRB1 DQA1 DQB1 Effect on GD a Effect on HT a Effect on AITD-T1D a
Ref. no. Ref. no.
*01:01 *01:01 *05:01 P 24 (DR1), 52 (DR1), 21 (DRB1),26 (DQB1), 27 (DQB1) – –
*03:01 *05:01 *02:01 S 21 (DRB1), 29 (DRB1), 27 (DQA1) S 53 (DR3), 7 (DQB1) S 57 (DQB1)
*04:01 *03:01 *03:02 P 54 (DQB1) S 6 (DQA1), 7 –
*04:01 *03:03 *03:01 – S 6 (DQB1), 55 (DRB1*04-DQB1) –
*04:05 *03:01 *03:02 – S 7 (DRB1), 6 (DQA1) –
*04:05 *03:03 *04:01 S 56 – N 58 (DRB1)
*07:01 *02:01 *02:02 P 21 (DRB1), 29 (DRB1) P 7 (DRB1*07), 6 (DRB1*07-DQA1-DQB1*02) –
*08:02 *03:01 *03:02 S 29 (DRB1) – –
*08:02 *04:01 *04:02 S 29 (DRB1) S 6 (DRB1*08-DQA1-DQB1*04) –
*08:03 *01:03 *06:01 S 20-22 S 23 b –
*09:01 *03:02 *03:03 – S 22, 23 b N 58 (DRB1)
*12:02 *06:01 *03:01 P 21 (DRB1), 54 (DRB1) – –
*13:02 *01:02 *06:04 P 21 (DRB1), 29 (DRB1) P 7 (DQB1), (DRB1*13-DQA1-DQB1*06), 23 b –
*14:03 *05:01 *03:01 S 29 (DRB1), 20 – –
*15:01 *01:02 *06:02 S/P 54 (DRB1) / 27 (DQB1) P 24 (DR2), 25 (DR2), 6 (DRB1*15-DQA1-DQB1*06), 23 b, 26 –
*15:02 *01:03 *06:01 – P 24 (DR2), 25 (DR2), 6 (DRB1*15-DQA1-DQB1*06) –
*16:02 *01:02 *05:02 S 54 (DRB1), 21 – –
a Effect on GD, HT, or AITD-T1D is classified as: S, susceptible; N, neutral; P, protective.
b HT-T1D
Table 3. Effects of HLA DR-DQ genes on GD, HT, or AITD
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With the exception of the DRB1*15:01-DQA1*01:02-DQB1*06:02 haplotype, there are no
controversial results concerning susceptibility and resistance to AITD. Additionally, except
for the DRB1*04:01-DQA1*03:01-DQB1*03:02 haplotype, no haplotype has been found to have
an adverse effect on GD and HT. Chen et al. demonstrated, for the first time, that the
DRB1*15:01 allele confers susceptibility to GD and that the DQB1*03:02 allele confers protec‐
tion against GD in the Taiwan Chinese population [54]. Further investigations in other ethnic
groups may be necessary to confirm whether their conclusions are widely applicable.
5. T1D-AITD and T1D+AITD
Few previous reports have been published on the relationship between HLA class II and T1D-
AITD. In contrast, there are a number of reports concerning the relationship between HLA
class II and T1D+AITD, which includes T1D+GD and T1D+HT. The results are shown in Table
4. As in Table 3, alleles in parentheses following the reference number indicate that the
reference reported susceptibility or resistance of the allele, but not the haplotype, to the disease.
There is no parenthesis following the reference number if the references reported the suscept‐
ibility or resistance of 4-digit DRB1-DQB1, DQA1-DQB1, or DRB1-DQA1-DQB1 haplotypes
to the disease. In cases with more than 2 haplotypes sharing the same allele, the allele is listed
redundantly in each haplotype. However, with consideration of the ethnicities that the
references examined, the allele may be removed from the corresponding haplotypes.
DRB1 DQA1 DQB1 Effect on T1D-AITD a Effect on T1D+AITD a
Ref no. Ref no.
*01:01 *01:01 *05:01 S 59 P 18 (DR1), 63b (DQB1*05)
*03:01 *05:01 *02:01 S 57 (DQB1), 60 S 18 (DR3), 57 (DQB1), 60
*04:01 *03:01 *03:02 S 57 (DQB1) S 18 (DR4), 63b (DQB1), 57 (DQB1)
*04:05 *03:01 *03:02 S 60 N 60
*04:05 *03:03 *04:01 S/N 61 (DR4) / 60 S 58 (DRB1), 22, 59, 60
*07:01 *02:01 *02:02 – N 18 (DR7)
*08:02 *03:01 *03:02 S 61 (DQA1) S 61c (DQA1), 22c, 59
*08:02 *04:01 *04:02 – S 22
*08:03 *01:03 *06:01 P 61 (DQA1) P 61 (DQA1)
*09:01 *03:02 *03:03 S 59 S 62 (DR9), 58 (DRB1), 22, 59
*13:02 *01:02 *06:04 S 59 P 18 (DR6), 60 (DR13)
*15:01 *01:02 *06:02 P 62 (DR2), 57 (DQB1), 59 P 18 (DR2), 62 (DR2), 57 (DQB1), 59
*15:02 *01:03 *06:01 P 62 (DR2), 61 (DQA1) P 62 (DR2), 61c (DQA1)
a Effect on T1D-AITD or T1D+AITD is classified as: S, susceptible; N, neutral; P, protective.
b T1D+HT; c T1D+GD
Table 4. Effects of HLA DR-DQ genes on T1D-AITD and T1D+AITD
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6. Relationship between GD and amino acid
Badenhoop et al. demonstrated that Arg at position 52 of the DQα1 chain plays an important
role in susceptibility to GD [27]. It was recently shown that Arg at position 74 of the DRβ1
chain is important for the development of GD in a significant number of patients [16, 17].
Further analysis has shown that the presence of Gln at position 74 of the DRβ1 chain was
protective for GD [16]. Table 5 shows the susceptibility and resistance of HLA DR-DQ genes
to GD, and amino acids at position 74 of the DRβ1 chain and position 52 of the DQα1 chain.
When more than 2 references reported susceptibility, we considered that the haplotype confers
susceptibility to GD (abbreviated as “S”). When more than 2 references reported protection
against the disease, we considered that the haplotype confers protection against GD (abbre‐
viated as “P”). When only one reference reported susceptibility, we considered that the
haplotype either confers susceptibility or is neutral to GD (abbreviated as “S/N”). When only
one reference reported a protective effect, we considered that the haplotype either confers
protection against or is neutral to GD (abbreviated as “P/N”). Badenhoop et al. showed that
susceptibility to GD is conferred by the DQA1*05:01 allele as well as Arg at position 52 of the
DQα1 chain [27]. DRβ-Arg-74 and DRβ-Gln-74 are always present on DR3 and DR7, respec‐
tively [16]. These amino acids are indicated in bold. The amino acids at position 52 of the
DQα1 chain that are encoded by the haplotypes listed in Table 5 are Arg, Gln, and Ser. The
effect on GD of the haplotypes which encode Arg or Ser at position 52 of the DQα1 chain varies
from susceptible to protective. Amino acids at position 74 of the DRβ1 chain that are encoded
by the haplotypes listed in Table 5 are Ala, Arg, Gln, and Leu. The effect on GD of these
haplotypes also varies from susceptible to protective. However, haplotypes that encode Leu
at position 74 of the DRβ1 chain, indicated by italics, are virtually all susceptible to GD.
Interestingly, DR3 encodes Arg at both position 52 of the DQα1 chain and position 74 of the
DRβ1 chain. Moreover, 3 of 4 haplotypes that encode Leu at position 74 of the DRβ1 chain
encode Arg at position 52 of the DQα1 chain. These findings may indicate that amino acids at
position 74 of the DRβ1 chain, rather than those at position 52 of the DQα1 chain, play an
important role in susceptibility or protection for GD.
7. Relationship between T1D±AITD and amino acid
It is well known that DQα-Arg-52 confer susceptibility to T1D [15]. Todd et al. demonstrated
that DQβ-Asp-57 is neutral or negatively associated with T1D, and that Ala, Val, or Ser at
position 57 of the DQβ1 chain is positively associated with T1D [13]. Table 6 lists the amino
acids at position 52 of the DQα1 chain and position 57 of the DQβ1 chain in each haplotype.
Although the effect on T1D of haplotypes with both DQα-Arg-52 and DQβ-Asp-57 is usually
protective or neutral, DRB1*04:05-DQA1*03:03-DQB1*04:01 and DRB1*09:01-DQA1*03:02-
DQB1*03:03 haplotypes confer susceptibility to T1D. In addition, the effect of some haplotypes
with Ala, Val, or Ser at position 57 of the DQβ1 chain on T1D is protective or neutral
(DRB1*01:01-DQA1*01:01-DQB1*05:01, DRB1*07:01-DQA1*02:01-DQB1*02:02, DRB1*13:02-
DQA1*01:02-DQB1*06:04, and DRB1*16:02-DQA1*01:02-DQB1*05:02). In Table 6, areas of the
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effect on T1D are shaded in the haplotypes that conflict with the theory that DQα-Arg-52 or
“non-Asp” at position 57 of the DQβ1 chain confers susceptibility to T1D, and that DQβ-Asp-57
confers protection against T1D.
Table 6 also shows the effects of HLA DR-DQ genes on AITD, T1D-AITD, and T1D+AITD.
When more than 2 references reported susceptibility to the disease, we considered that the
haplotype confers susceptibility (abbreviated as “S”), regardless of a single report demon‐
strating that the haplotype confers protection against the disease. When more than 2 references
reported protection against the disease, we considered that the haplotype confers protection
(abbreviated as “P”), regardless of one report demonstrating to the disease. When only one
reference reported susceptibility, we considered that the haplotype confers susceptibility or is
neutral (abbreviated as “S/N”). When only one reference reported protection against the
disease, we considered that the haplotype confers protection or is neutral (abbreviated as “P/
N”). Recently, Menconi et al. demonstrated that amino acids at position 74 of the DRβ1 chain
play an important role in susceptibility and resistance to APS-3A, i.e., T1D+AITD as well as
GD [18]. DRβ-Tyr-26, DRβ-Leu-67, DRβ-Lys-71, and DRβ-Arg-74 are positively associated
with APS-3A, while DRβ-Ala-71 and DRβ-Gln-74 are negatively associated with APS-3A.
These amino acids are indicated in bold in Table 6.
DRB1 DQA1 DQB1 Effect on GD a Amino acid at position 52 ofDQα1 chain
Amino acid at position 74 of DRβ1
chain
*01:01 *01:01 *05:01 P Ser Ala
*03:01 *05:01 *02:01 S Arg Arg
*04:01 *03:01 *03:02 P/N Arg Ala
*04:05 *03:03 *04:01 S/N Arg Ala
*07:01 *02:01 *02:02 P Gln Gln
*08:02 *03:01 *03:02 S/N Arg Leu
*08:02 *04:01 *04:02 S/N Arg Leu
*08:03 *01:03 *06:01 S Ser Leu
*12:02 *06:01 *03:01 P Arg Ala
*13:02 *01:02 *06:04 P Ser Ala
*14:03 *05:01 *03:01 S Arg Leu
*15:01 *01:02 *06:02 S/N, P/N Ser Ala
*16:02 *01:02 *05:02 S Ser Ala
a Effect on GD is classified as: S, susceptible; P, protective; S/N, susceptible or neutral; P/N, protective or neutral.
Table 5. Relationship between effect on GD and amino acids
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In this section, we discuss the relationship between the above-mentioned HLA DR-DQ genes,
amino acids at positions 26, 67, 71, and 74 of the DRβ1 chain, and T1D with or without AITD.
DRB1*01:01-DQA1*01:01-DQB1*05:01 and DRB1*13:02-DQA1*01:02-DQB1*06:04 haplotypes
While these haplotypes encode Val at position 57 of the DQβ1 chain, they confer protection or
are neutral to T1D. Although they confer protection against AITD and T1D+AITD, they tend
to confer susceptibility to T1D-AITD (S/N in Table 6). Since 15 to 30% of subjects with T1D
have AITD [44–46], the effect of AITD on T1D may result in resistance of subjects with these
haplotypes to T1D.
DRB1*04:05-DQA1*03:03-DQB1*04:01 and DRB1*09:01-DQA1*03:02-DQB1*03:03 haplotypes
DRB1 DQA1 DQB1 Effect of HLA DR-DQ gene DQα1 DQβ1 DRβ1
AITD a T1D-AITD a T1D b T1D+AITD a 52 57 26 67 71 74
*01:01 *01:01 *05:01 P S/N P P Ser Val Leu Leu Arg Ala
*03:01 *05:01 *02:01 S S S S Arg Ala Tyr Leu Lys Arg
*04:01 *03:01 *03:02 S S/N S S Arg Ala Phe Leu Lys Ala
*04:01 *03:03 *03:01 S – P – Arg Asp Phe Leu Lys Ala
*04:05 *03:01 *03:02 S S/N S N Arg Ala Phe Leu Arg Ala
*04:05 *03:03 *04:01 S/N S/N S S Arg Asp Phe Leu Arg Ala
*07:01 *02:01 *02:02 P – P N Gln Ala Phe Ile Arg Gln
*08:02 *03:01 *03:02 S/N S/N S S Arg Ala Phe Phe Arg Leu
*08:02 *04:01 *04:02 S – N S/N Arg Asp Phe Phe Arg Leu
*08:03 *01:03 *06:01 S P/N P P/N Ser Asp Phe Ile Arg Leu
*09:01 *03:02 *03:03 S S/N S S Arg Asp Tyr Phe Arg Glu
*12:02 *06:01 *03:01 P – P – Arg Asp Leu Phe Arg Ala
*13:02 *01:02 *06:04 P S/N N P Ser Val Phe Ile Glu Ala
*14:03 *05:01 *03:01 S – P – Arg Asp Phe Leu Arg Leu
*15:01 *01:02 *06:02 P P P P Ser Asp Phe Ile Ala Ala
*15:02 *01:03 *06:01 P P P P Ser Asp Phe Ile Ala Ala
*16:02 *01:02 *05:02 S – N – Ser Ser Phe Leu Arg Ala
a Effect on AITD, T1D-AITD, or T1D+AITD is classified as: S, susceptible; P, protective; S/N, susceptible or neutral; P/N,
protective or neutral.
b Effect on T1D is classified as: S, susceptible; N, neutral; P, protective.
Table 6. Effects of HLA DR-DQ genes on AITD, T1D-AITD, T1D, or T1D+AITD
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These haplotypes are the major haplotypes which confer susceptibility to T1D in East Asians,
especially in the Japanese population where the DR3 haplotype is absent and the DR4
haplotype is rare [8–10]. While these haplotypes encode Asp at position 57 of the DQβ1 chain,
they confer susceptibility to T1D+AITD. DRβ-Leu-67 in the DRB1*04:05-DQA1*03:03-
DQB1*04:01 haplotype and DRβ-Tyr-26 in the DRB1*09:01-DQA1*03:02-DQB1*03:03 haplo‐
type might play an important role in susceptibility to T1D+AITD. Since 15 to 30% of subjects
with T1D have AITD [44–46], the effect of these amino acids on T1D may be susceptibility, and
that on T1D-AITD might be susceptibility or neutrality, which is weaker than that on T1D or
T1D+AITD.
DRB1*07:01-DQA1*02:01-DQB1*02:02 and DRB1*16:02-DQA1*01:02-DQB1*05:02 haplotypes
There are few reports concerning the effect of HLA DR-DQ genes on T1D-AITD in the
Caucasian [57], Japanese [59, 61, 62], and Taiwan Chinese [60] populations (Table 4). The
DRB1*07:01-DQA1*02:01-DQB1*02:02 and DRB1*16:02-DQA1*01:02-DQB1*05:02 haplotypes
are rare in the Japanese population [8–10, 49]. Therefore, it is difficult to explain the protective
or neutral effect of these haplotypes with “non-Asp” at position 57 of the DQβ1 chain on T1D
by examining the effect of these haplotypes on T1D-AITD. However, Menconi et al. demon‐
strated that DRβ-Gln-74 is negatively associated with T1D+AITD, although they failed to
demonstrate that the DR7 allele, which encodes Gln at position 74 of the DRβ1 chain, confers
protection against T1D+AITD [18] (Table 6). The DR3 and DR4 haplotypes encode Ala at
position 57 of the DQβ1 chain, which confers strong susceptibility to T1D [2]. Since the DR7
haplotype also encodes Ala at position 57 of the DQβ1 chain, the effect of this haplotype might
potentially result in susceptibility to T1D-AITD. Since 15 to 30% of subjects with T1D have
AITD [44–46], DRβ-Gln-74 might play a role in protection against T1D.
There are several reports concerning the effect of HLA DR-DQ genes on T1D+AITD, which
also studied Caucasian [18, 57, 63], Japanese [22, 58, 59, 61, 62], and Taiwan Chinese [60]
populations (Table 4). The DRB1*16:02-DQA1*01:02-DQB1*05:02 haplotype is rare in the
Caucasian population as well as in the Japanese population [49], and Menconi et al. did not
examine patients and controls with the DR16 allele [18]. Moreover, the positive effect of DQβ-
Ser-57 on T1D is weaker than that of DQβ-Ala-57 or DQβ-Val-57 [2]. To our knowledge, the
evidence of the effect of the DRB1*16:02-DQA1*01:02-DQB1*05:02 haplotype on T1D is
insufficient.
8. Conclusion
T1D and AITD share common genetic risk factors. The prevalence of given HLA haplotypes
varies among populations, but given the same DR and DQ haplotypes, the influence of HLA
on T1D and/or AITD is similar on populations throughout the world. By clarifying the region
of the diseases on which certain reports were focused, we can explain to some extent and
speculate on the relationship between HLA haplotypes, specific amino acids, and T1D and/or
AITD.
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